In April 2017, DNDand GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis which were discovered by GSK in collaboration with the Drug Discovery Unit (DDU) at the University of Dundee, following some co-funding by the Wellcome Trust.

Project updates

2019

A Phase I single ascending dose study of GSK3186899/DDD853651 in healthy volunteers was completed in 2019; a Phase I single ascending dose study of GSK3494245/DDD1305143 is planned to start in late 2020.

2018

GSK3186899/DDD853651 was nominated as a clinical candidate in 2018. GSK3494245/DDD1305143 is currently under review to assess the feasibility of proceeding to a Phase I study.